Antitumor Necrosis Factor (TNF-a) Antibodies in the Treatment of Renal Cell Cancer

Autor:	Nick Maisey
Rok vydání:	2007
Předmět:	Cancer Research Necrosis medicine.drug_class medicine.medical_treatment Antineoplastic Agents urologic and male genital diseases Monoclonal antibody Clinical Trials Phase II as Topic Renal cell carcinoma medicine Humans Carcinoma Renal Cell Tumor Necrosis Factor-alpha Sunitinib business.industry Antibodies Monoclonal General Medicine medicine.disease Infliximab Kidney Neoplasms female genital diseases and pregnancy complications Thalidomide Cytokine Oncology Immunology Cancer research Tumor necrosis factor alpha medicine.symptom business medicine.drug
Zdroj:	Cancer Investigation. 25:589-593
ISSN:	1532-4192 0735-7907
Popis:	The kinase inhibitors sorafinib and sunitinib have demonstrated significant activity in renal cell carcinoma (RCC), and are now approved by the FDA for use in advanced disease. There still remains a need for novel therapies. Our group were the first to demonstrate activity of thalidomide in RCC, believed to be in part related to the modulation of tumor necrosis factor (TNF-a), a cytokine secreted by RCC with a number of tumor promoting properties. We subsequently conducted a phase II trial of the TNF-a monoclonal antibody infliximab in patients with previously treated advanced RCC. The drug was well tolerated. The response rate was 16% and stability was achieved in a further 16% of patients. Anti-TNF-a therapy may represent an important approach in the treatment of this disease.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7731a2895fb5b3bacbbf7144ffda0821 https://doi.org/10.1080/07357900701359700 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.